QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Diabetes Related Complications
Interventions
DEVICE

Holter and Glucose monitoring

"(i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.~(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities."

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Royal Prince Alfred Hospital, Sydney, Australia

OTHER

NCT02298803 - QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia | Biotech Hunter | Biotech Hunter